ScreenerHero
OXBOxford Biomedica PLC
LSE · GB · Healthcare · Biotechnology · oxb.com
520.00GBP+2.56%Mkt Cap: 787.13M $P/E: —

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system wh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap787.13M $
Enterprise Value850.94M $
Revenue (TTM)216.43M $
Gross Profit84.63M $
Net Income (TTM)-38.64M $
Revenue/Share1.934 USD
Last Price520.00 GBP
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees977
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BDFBVT43
Valuation
P/E (Trailing)—
P/E (Forward)-125.54
PEG—
EV/EBITDA-36.33
EV/Revenue3.93
P/S3.77
P/B6.94
EPS (TTM)-0.27
EPS (Forward)-0.04
52W Range
441.5015% of range962.00
52W High962.00 GBP
52W Low441.50 GBP
Profitability
Gross Margin39.10%
Oper. Margin-7.88%
EBITDA Margin-10.82%
Profit Margin-17.85%
ROE-32.98%
ROA-9.25%
Growth
Revenue Growth22.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF650.28K $
CapEx (TTM)6.11M $
FCF Margin-0.01%
FCF Yield-0.00%
Net Debt65.70M $
Net Debt/EBITDA-2.81
Balance Sheet
Debt/Equity1.62
Current Ratio2.20
Quick Ratio1.92
Book Value/Sh0.7560 GBP
Cash/Share0.8020 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 30, 2018
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)712.00 GBP
Upside (mean)+36.9%
Target Range508.00 GBP – 900.00 GBP
GBP508.00+36.9% to meanGBP900.00
# Analysts8
Ownership
Shares Out.121.04M
Float60.83M
Insiders20.55%
Institutions55.25%
Technical
SMA 50583.97 (-11.0%)
SMA 200641.60 (-19.0%)
Beta1.10
S&P 52W Chg18.16%
Avg Vol (30d)692.24K
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)38.3
MACD-29.0728
MACD Signal-25.8302
MACD Hist.-3.2427
BB Upper623.23 GBP
BB Middle540.35 GBP
BB Lower457.47 GBP
BB Width30.68%
ATR (14)29.36 GBP
Vol Ratio (20d)0.28x